Nintedanib is a multikinase inhibitor inhibiting the receptor tyrosine kinase of platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), and transforming growth factor-beta (TGFβ) [179], thus targeting several molecular pathways involved in the pathogenesis of IPF, such as fibroblast proliferation, migration and differentiation, and the secretion of ECM. This evidence concerns the gene VEGFA and idiopathic pulmonary fibrosis.